Alexion Pharmaceuticals
E505487
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| acquiredBy | AstraZeneca NERFINISHED ⓘ |
| acquisitionAnnouncedOn | 2020-12-12 ⓘ |
| acquisitionCompletedOn | 2021-07-21 ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| developsTreatmentFor |
atypical hemolytic uremic syndrome
ⓘ
generalized myasthenia gravis ⓘ hypophosphatasia ⓘ lysosomal acid lipase deficiency ⓘ neuromyelitis optica spectrum disorder NERFINISHED ⓘ paroxysmal nocturnal hemoglobinuria ⓘ |
| divisionOf | AstraZeneca Rare Disease NERFINISHED ⓘ |
| focusesOn | complement-mediated disorders ⓘ |
| formerHeadquartersLocation | New Haven, Connecticut, United States NERFINISHED ⓘ |
| foundedBy |
Leonard Bell
NERFINISHED
ⓘ
Stephen Squinto NERFINISHED ⓘ |
| foundedIn | 1992 ⓘ |
| hasEmployeeCountRange | >= 3000 employees (approximate) ⓘ |
| headquartersLocation | Boston, Massachusetts, United States NERFINISHED ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| keyDrug |
eculizumab
ⓘ
ravulizumab NERFINISHED ⓘ |
| listedOn | NASDAQ ⓘ |
| notableProduct |
Andexxa
NERFINISHED
ⓘ
Kanuma NERFINISHED ⓘ Soliris NERFINISHED ⓘ Strensiq NERFINISHED ⓘ Ultomiris NERFINISHED ⓘ |
| parentCompany | AstraZeneca NERFINISHED ⓘ |
| regulatoryApproval |
FDA approval for Kanuma in LAL-D
ⓘ
FDA approval for Soliris in NMOSD ⓘ FDA approval for Soliris in PNH ⓘ FDA approval for Soliris in aHUS ⓘ FDA approval for Soliris in gMG ⓘ FDA approval for Strensiq in hypophosphatasia ⓘ FDA approval for Ultomiris in PNH ⓘ FDA approval for Ultomiris in aHUS ⓘ |
| researchFocus |
complement inhibition
ⓘ
rare hematologic diseases ⓘ rare metabolic diseases ⓘ rare neurologic diseases ⓘ rare renal diseases ⓘ |
| specializesIn |
complement biology
ⓘ
therapies for rare diseases ⓘ therapies for severe diseases ⓘ |
| tickerSymbol | ALXN NERFINISHED ⓘ |
| website | https://alexion.com ⓘ |
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.